COMP <GO>
CLYM vs ACRS // EV/EBITDA & P/E VALUATION
Climb Bio Inc. (NASDAQ) VS. Aclaris Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CLYM 1
— ACRS 3
■ METRIC PARITY
LAST: $10.33 (+2.08%) • MKT CAP: $593.3M
valuation
—
LAST: $3.99 (+0.76%) • MKT CAP: $587.3M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLYM VS. ACRS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLYM | ACRS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 73.30% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.19% | -8.04% | -1.15 | ACRS | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -58.20% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | ACRS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.1 | 45.5 | -1.40 | ACRS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $593.3M | $587.3M | $6.0M | CLYM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLYM REV | ACRS REV | CLYM GROSS % | ACRS GROSS % | CLYM FCF | ACRS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $7.8M | — | 73.3% | -$54.5M | -$47.2M |
| FY 2024 | $0 | $18.7M | — | 85.1% | -$15.6M | -$20.2M |
| FY 2023 | $0 | $31.2M | — | — | -$20.6M | -$78.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLYM // BETA —
ACRS // BETA —